Litmys, LLC Founder and Managing Partner Harris Kaplan published an article analyzing the commercial realities behind the GLP-1 gold rush, including entrenched prescribing habits, payer dynamics, incumbent defenses, and increasing price pressure.

Litmys is a boutique commercial strategy consulting firm helping life science companies ensure products succeed beyond approval. We partner with pharmaceutical, biotech, diagnostics, and medical device innovators to uncover and strengthen the real-world adoption drivers that determine commercial success, ideally while products are still in development. With 40+ years of experience and insights from 125+ product launches, Litmys integrates market, clinical, and payer perspectives to reduce risk and improve late-stage ROI. Led by CEO Harris Kaplan, Litmys provides hands-on, senior-level support, data-driven analytics, and proven methodologies to get products market-ready faster. What We Do • Commercial Viability Assessments: Test differentiation and adoption readiness. • Portfolio & Indication Prioritization: Identify highest-ROI opportunities. • Clinical & Commercial Alignment: Ensure endpoints, evidence, and messaging meet payer, physician, and patient needs. • Investor & Board Communication: Translate insights into compelling, evidence-based narratives. Our Approach Our proprietary RAMPx™ model quantifies adoption potential across 12 real-world drivers, the only framework measuring how compelling a product’s value proposition is versus the standard of care. We prefer to engage early (before Phase 3) when strategy and ROI can still be shaped, helping clients make confident Go / No-Go / Let’s Revisit decisions. Why Clients Choose Litmys • Four decades of life science commercialization experience. • Direct, hands-on CEO involvement. • Agility of a senior-led, focused firm. • Proprietary, predictive tools linking development to outcomes. • A track record of stronger launches, clearer investor messaging, and smarter portfolio choices.